Meningococcemia secondary prevention: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
 
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
{{Meningococcemia}}
{{Meningococcemia}}
{{CMG}}
==Overview==
The most important form of prevention is a vaccine against ''[[Neisseria meningitidis]]''.  Different countries have different strains of the bacteria and therefore use different vaccines.  Five serogroups, A, B, C, Y and W135 are responsible for virtually all cases of the disease in humans. Vaccines are currently available against four of the five strains, and a vaccine against the B strain is in development. Menactra and Menomune are two commonly used vaccines. Unfortunately, there is currently no evidence that any of the current vaccines offer significant protection beyond three years. Additionally, basic [[hygiene]] measures, such as hand washing and not sharing drinking cups, can reduce the incidence of infection by limiting exposure. When a case is confirmed, all close contacts with the infected person can be offered [[antibiotics]] to reduce the likelihood of the infection spreading to other people.
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Needs overview]]
[[Category:Needs content]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Infectious disease]]
 
[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Pediatrics]]
[[Category:Pediatrics]]

Latest revision as of 18:03, 18 September 2017